Peritumoral Lidocaine Injection: A Low-Cost, Easily Implemented Intervention to Improve Outcomes in Early-Stage Breast Cancer
Mené sur 1 583 patientes atteintes d'un cancer du sein de stade précoce et devant bénéficier d'une chirurgie (durée médiane de suivi : 68 mois), cet essai randomisé multicentrique évalue l'effet, sur la survie sans maladie et la survie globale, d'une injection péritumorale de lidocaïne avant la chirurgie
Improvements in breast imaging and the routine use of breast cancer screening have resulted in increased rates of breast cancer cases diagnosed at early stages of disease, before metastatic dissemination. Additionally, advances in local regional and systemic therapies have significantly decreased the likelihood that patients treated for early-stage disease will recur. Despite these advances, it is generally thought that up to 30% of women treated for early-stage breast cancer eventually develop metastatic disease, suggesting additional opportunities to identify effective interventions to prevent breast cancer recurrence. One opportunity that has not been studied extensively is to intervene in the immediate perioperative period.
Journal of Clinical Oncology , éditorial en libre accès, 2022